Food Additives Permitted for Direct Addition to Food for Human Consumption; Vitamin D3, 69435-69438 [05-22670]
Download as PDF
Federal Register / Vol. 70, No. 220 / Wednesday, November 16, 2005 / Rules and Regulations
10. In Supplement No. 1 to part 774
(the Commerce Control List), Category
3—Electronics, Export Control
Classification Number (ECCN) 3A992 is
amended by revising the License
Requirements section to read as follows:
5A991 Telecommunication equipment, not
controlled by 5A001.
License Requirements
Reason for Control: AT.
Control(s)
Country chart
3A992 General purpose electronic
equipment not controlled by 3A002.
License Requirements
Reason for Control: AT.
AT applies to entire entry ......
AT Column 1.
I
Control(s)
Country chart
AT applies to entire entry ......
AT Column 1.
See §§ 740.19 and 742.20 of the EAR for
additional information on Libya.
*
*
*
*
*
I 11. In Supplement No. 1 to part 774
(the Commerce Control List), Category
3—Electronics, Export Control
Classification Number (ECCN) 3B992 is
amended by revising the License
Requirements section to read as follows:
3B992 Equipment not controlled by 3B002
for the inspection or testing of Electronic
components and materials, and specially
designed components and accessories
therefor.
License Requirements
Reason for Control: AT.
Control(s)
Country chart
AT applies to entire entry ......
AT Column 1.
See §§ 740.19 and 742.20 of the EAR for
additional information on Libya.
*
*
*
*
*
12. In Supplement No. 1 to part 774
(the Commerce Control List), Category
4—Computers, Export Control
Classification Number (ECCN) 4A994 is
amended by revising the License
Requirements section to read as follows:
I
4A994 Computers, ‘‘electronic assemblies’’,
and related equipment not controlled by
4A001 or 4A003, and specially designed
components therefor.
License Requirements
Reason for Control: AT.
*
*
*
*
*
14. In Supplement No. 1 to part 774
(the Commerce Control List), Category
5—Telecommunications and
‘‘Information Security’’—Information
Security, Export Control Classification
Number (ECCN) 5A992 is amended by
revising the License Requirements
section to read as follows:
I
5A992 Equipment not controlled by 5A002.
License Requirements
Reason for Control: AT.
Control(s)
Country chart
AT applies to 5A992.a ..........
AT applies to 5A992.b ..........
AT Column 1.
AT Column 2.
See §§ 740.19 and 742.20 of the EAR for
additional information on Libya.
*
*
*
*
*
I 15. In Supplement No. 1 to part 774
(the Commerce Control List), Category
5—Telecommunications and
‘‘Information Security’’—Information
Security, Export Control Classification
Number (ECCN) 5D992 is amended by
revising the License Requirements
section to read as follows:
5D992 ‘‘Information Security’’ ‘‘software’’
not controlled by 5D002.
License Requirements
Reason for Control: AT.
Control(s)
Country chart
AT applies to 5D992.a.1 and
.b.1.
AT applies to 5D992.a.2, b.2
and c.
AT Column 1.
AT Column 2.
Control(s)
Country chart
See §§ 740.19 and 742.20 of the EAR for
additional information on Libya.
AT applies to entire entry ......
AT Column 1.
*
*
*
*
*
13. In Supplement No. 1 to part 774
(the Commerce Control List), Category
5—Telecommunications and
Information Security’’—
Telecommunications, Export Control
Classification Number (ECCN) 5A991 is
amended by revising the License
Requirements section to read as follows:
I
VerDate Aug<31>2005
11:21 Nov 15, 2005
Jkt 208001
*
*
*
*
16. In Supplement No. 1 to part 774
(the Commerce Control List), Category
9—Propulsion Systems, Space Vehicles
and Related Equipment, Export Control
Classification Number (ECCN) 9A990 is
amended by revising the License
Requirements section to read as follows:
I
See §§ 740.19 and 742.20 of the EAR for
additional information on Libya.
*
Control(s)
Country chart
AT applies to entire entry except 9A990.a.
AT applies to 9A990.a only ...
AT Column 1.
9A990 Diesel engines, n.e.s., and tractors
and specially designed parts therefor, n.e.s.
License Requirements
Reason for Control: AT.
PO 00000
Frm 00015
Fmt 4700
Sfmt 4700
AT Column 2.
See §§ 740.19 and 742.20 of the EAR for
additional information on Libya.
*
See §§ 740.19 and 742.20 of the EAR for
additional information on Libya.
69435
*
*
*
*
Dated: November 9, 2005.
Matthew S. Borman,
Deputy Assistant Secretary for Export
Administration.
[FR Doc. 05–22674 Filed 11–15–05; 8:45 am]
BILLING CODE 3510–33–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 172
[Docket No. 2004F–0374]
Food Additives Permitted for Direct
Addition to Food for Human
Consumption; Vitamin D3
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final rule.
SUMMARY: The Food and Drug
Administration (FDA) is amending the
food additive regulations to provide for
the safe use of vitamin D3 as a nutrient
supplement in cheese and cheese
products at a level above that currently
allowed by the regulations. This action
is in response to a petition filed by Kraft
Foods Global, Inc. (Kraft).
DATES: This rule is effective November
16, 2005. Submit written or electronic
objections and requests for a hearing by
December 16, 2005. See Section VI of
this document for information on the
filing of objections.
ADDRESSES: You may submit written
objections and requests for a hearing,
identified by Docket No. 2004F–0374,
by any of the following methods:
Electronic Submissions
Submit electronic objections in the
following ways:
• Federal eRulemaking Portal: https://
www.regulations.gov.
Follow the instructions for submitting
comments.
• Agency Web site: https://
www.fda.gov/dockets/ecomments.
Written Submissions
Submit written submissions in the
following ways:
• FAX: 301–827–6870.
• Mail/Hand delivery/Courier [For
paper, disk, or CD–ROM submissions]:
E:\FR\FM\16NOR1.SGM
16NOR1
69436
Federal Register / Vol. 70, No. 220 / Wednesday, November 16, 2005 / Rules and Regulations
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
To ensure more timely processing of
objections, FDA is no longer accepting
objections submitted to the agency by email. FDA encourages you to continue
to submit electronic objections by using
the Federal eRulemaking Portal or the
agency Web site, as described in the
Electronic Submissions portion of this
paragraph.
Instructions: All submissions received
must include the agency name and
docket number for this rulemaking. All
objections received will be posted
without change to https://www.fda.gov/
ohrms/dockets/default.htm, including
any personal information provided. For
detailed instructions on submitting
objections, see the ‘‘Objections’’ heading
of the SUPPLEMENTARY INFORMATION
section of this document.
Docket: For access to the docket to
read background documents or
objections received, go to https://
www.fda.gov/ohrms/dockets/
default.htm and insert the docket
number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Judith L. Kidwell, Center for Food
Safety and Applied Nutrition (HFS–
265), Food and Drug Administration,
5100 Paint Branch Pkwy., College Park,
MD 20740, 301–436–1071.
SUPPLEMENTARY INFORMATION:
I. Introduction
In a notice published in the Federal
Register of September 9, 2004 (69 FR
54687), FDA announced that a food
additive petition (FAP 4A4758) had
been filed by Kraft Foods Global, Inc.,
c/o Hogan and Hartson, 555 13th St.
NW., Washington, DC 20004. The
petition proposed to amend the food
additive regulations in § 172.380
Vitamin D3 (21 CFR 172.380) to permit
the use of vitamin D3 in cheese and
cheese products at a level above that
permitted in § 184.1950 Vitamin D (21
CFR 184.1950). Currently, under
§ 184.1950, milk products, which
include cheese and cheese products,
may be fortified with vitamin D at a
level up to 89 International Units (IU)
per (/) 100 grams (g). The petitioner
requested that the maximum amount of
vitamin D permitted in certain natural
and processed cheeses be increased to
81 IU vitamin D3/30 g. Cheese and
cheese products identified in the
VerDate Aug<31>2005
14:53 Nov 15, 2005
Jkt 208001
petition for increased fortification levels
are those with a reference amount
customarily consumed (RACC) of 30 g
as defined in § 101.12 (21 CFR 101.12),
including standardized and
nonstandardized natural cheese,
processed cheese, cream cheese, and
cheese spreads and dips. Hard grating
cheeses with smaller reference amounts,
such as Parmesan and Romano as
defined in §§ 133.165 and 133.183 (21
CFR 133.165 and 133.183), respectively,
and those defined by the standards of
identity in § 133.148 (21 CFR 133.148),
are not included, nor are cheeses with
larger reference amounts, such as
cottage cheese or ricotta cheese. Cheeselike products made from nondairy
starting materials (e.g., soy-based
products) are not considered to be
cheese and are not included. The new
limit would permit vitamin D to be
added to cheese and cheese products at
a level slightly more than 20 percent of
the reference daily intake (RDI) of
vitamin D/30 g serving. Under § 101.54
(21 CFR 101.54), food containing 10 to
19 percent of the RDI of a nutrient is
allowed to carry a label claim such as
‘‘good source’’ and if the level is 20
percent or more of the RDI, the food
label may claim ‘‘excellent source.’’
Under § 172.380, vitamin D3 is
approved for use as a nutrient
supplement in calcium-fortified fruit
juices, calcium-fortified fruit juice
drinks, meal replacement and other-type
bars, and soy-protein based meal
replacement beverages represented for
special dietary use in reducing or
maintaining body weight. Vitamin D 1,
including vitamin D3, also is affirmed as
generally recognized as safe (GRAS) for
use in food under § 184.1950 with the
following limitations:
Category of Food
Maximum Levels in
Food (as served)
Breakfast cereals
350 IU/100 g
Grain products and
pasta
90 IU/100 g
Milk
42 IU/100 g
Milk products
89 IU/100 g
Additionally, under § 184.1950(c)(2)
and (c)(3) vitamin D is affirmed as
GRAS for use in infant formula and
margarine, respectively.
1Vitamin D comprises a group of fat-souble secosterols and comes in many forms. The two major
physiologically relevant forms are vitamin D2 and
vitamin D3. Vitamin D without a subscript
represents either D2 or D3. As used in § 184.1950,
the meaning of the term vitamin D includes
crystalline vitamin D2, crystalline vitamin D3,
vitamin D2 resin, and vitamin D3 resin. Section
172.380 includes only crystalline vitamin D3.
PO 00000
Frm 00016
Fmt 4700
Sfmt 4700
Vitamin D3, also known as
cholecalciferol, is the chemical 9,10seco(5Z,7E)-5,7,10(19)-cholestatrien-3ol. Humans synthesize vitamin D3 in
skin from its precursor, 7–
dehydrocholesterol under exposure to
ultraviolet B radiation in sunlight. Other
sources of naturally occurring vitamin D
are foods such as butter, buttermilk,
cheese, cream, eggs, fish, goat milk,
meat fats and organ meats, and
mushrooms.
Vitamin D is essential for human
health. The major function of vitamin D
is to maintain blood serum
concentrations of calcium and
phosphorus by enhancing the
absorption of these minerals from the
small intestine. Vitamin D deficiency
can lead to abnormalities in calcium
and bone metabolism such as rickets in
children or osteomalacia in adults. At
high levels vitamin D may be toxic.
Excessive intake of vitamin D elevates
blood plasma calcium levels by
increased intestinal absorption and/or
mobilization from the bone.
To ensure that vitamin D is not added
to the U.S. food supply at levels that
could raise safety concerns, FDA
affirmed vitamin D as GRAS with
specific limitations, as listed in
§ 184.1950. Under 21 CFR 184.1(b)(2),
an ingredient affirmed as GRAS with
specific limitations may be used in food
only within such limitations, including
the category of food, functional use, and
level of use. Any addition of vitamin D
to food beyond those limitations set out
in § 184.1950 requires either a food
additive regulation or an amendment of
§ 184.1950.
To support the safety of the proposed
uses of vitamin D3, Kraft submitted
dietary intake estimates from current
and proposed uses and from naturallyoccurring sources of vitamin D and
compared these intake estimates to the
tolerable upper intake level (UL) for
vitamin D established by the Institute of
Medicine (IOM) of the National
Academies. Kraft also submitted a
number of publications pertaining to
human clinical studies on vitamin D.
Based on this information, which is
discussed in section II of this document,
the petitioner concluded that the
proposed use of vitamin D3 in cheese
and cheese products is safe.
II. Evaluation of Safety
To establish with reasonable certainty
that a food additive is not harmful
under its intended conditions of use,
FDA considers the projected human
dietary intake of the additive, the
additive’s toxicological data, and other
E:\FR\FM\16NOR1.SGM
16NOR1
Federal Register / Vol. 70, No. 220 / Wednesday, November 16, 2005 / Rules and Regulations
relevant information (such as published
literature) available to the agency. FDA
compares an individual’s estimated
daily intake (EDI) of the additive from
all sources to an acceptable intake level
established by toxicological data. The
EDI is determined by projections based
on the amount of the additive proposed
for use in particular foods and on data
regarding the amount consumed from
all sources of the additive. The agency
commonly uses the EDI for the 90th
percentile consumer of a food additive
as a measure of high chronic dietary
intake.
A. Estimated Daily Intake for Vitamin D
The petitioner provided mean and
90th percentile vitamin D intake
estimates for consumers of cheese and
cheese products from the following: (1)
The proposed food uses; (2) current
regulated food uses (including naturally
occurring sources of vitamin D); and (3)
dietary supplements.2 Intake estimates
for the U.S. population 2 years of age
and older were provided, as well as
estimates for 18 population subgroups,
including breast-fed and nonbreast-fed
infants 0 to 11 months of age. The
agency agrees with the methodology
used to calculate these estimates, with
the exception of intake estimates from
dietary supplements for infants 0 to 11
months of age.
For consumers 2 years of age and
older, Kraft estimated mean and 90th
percentile dietary intakes from current
(including naturally occurring sources)
and proposed food uses of vitamin D to
be 335 IU per person per day (IU/p/d)
and 582 IU/p/d, respectively. For breastfed infants 0 to 11 months of age, mean
and 90th percentile intakes were
estimated to be 180 IU/p/d and 322 IU/
p/d, respectively. For nonbreast-fed
infants 0 to 11 months of age, mean and
90th percentile intakes were estimated to
be 443 IU/p/d and 696 IU/p/d,
respectively. For children 1 to 3 years of
age, mean and 90th percentile intake
estimates were 383 IU/p/d and 583 IU/
p/d, respectively.
The petitioner also considered the
intake of vitamin D from dietary
supplements. The National Health and
Nutrition Examination Survey III
(NHANES III) data indicate that
approximately 33 percent of the U.S.
population 2 years of age and older take
dietary supplements. The NHANES III
data also show that, when vitamin D is
taken as a dietary supplement, the most
frequent level is 400 IU/p/d. As a
conservative estimate of intake of
2 The intake estimate included Parmesan cheese;
however, fortification of hard grating cheeses such
as Parmesan was not requested.
VerDate Aug<31>2005
11:21 Nov 15, 2005
Jkt 208001
vitamin D from dietary supplements and
conventional food, Kraft considered it
appropriate to assume that consumers of
cheese and cheese products who take
dietary supplements likely would take
dietary supplements containing 400 IU
of vitamin D. They then added this
value to the mean and 90th percentile
intake estimates from current and
proposed food uses for consumers 2
years of age and older. For consumers of
cheese and cheese products, mean and
90th percentile dietary intakes from
current and proposed food uses and
dietary supplements were estimated to
be 735 IU/p/d and 982 IU/p/d,
respectively, for consumers 2 years of
age and older. Kraft chose not to add a
value of 400 IU from supplement use to
intake estimates for infants 0 to 11
months of age due to the low percentage
of infants reported to use supplements
(7 percent) in the NHANES III study.
While we do not agree with Kraft’s
choice to exclude supplement use in the
vitamin D intake for infants, we believe
that, in light of recent recommendations
from the American Academy of
Pediatrics (AAP),3 estimating a
supplement intake of 200 IU/p/d is
more appropriate than 400 IU/p/d for
infants.
Based on AAP recommendations, the
agency assumed a vitamin D intake of
200 IU from supplement use for infants
0 to 11 months of age, resulting in
exposure estimates at the 90th
percentile of 522 IU/p/d and 896 IU/p/
d for breast-fed and nonbreast-fed
infants, respectively. For all other
populations (including children and
adolescents) we assumed a supplement
intake of 400 IU/p/d (Ref. 1).
B. Acceptable Daily Intake for Vitamin
D
In 1997, the Standing Committee on
the Scientific Evaluation of Dietary
Reference Intakes of the Food and
Nutrition Board at IOM conducted an
extensive review of toxicology and
metabolism studies on vitamin D
published through 1996. The IOM
published a detailed report that
3 ‘‘Prevention of Rickets and Vitamin D
Deficiency: New Guidelines for Vitamin D Intake,’’
from the American Academy of Pediatrics in:
Pediatrics Vol. III No. 4, pp. 908–910, April 2003.
The AAP recommends a daily vitamin D
supplement of 200 IU for the following groups:
• All breast-fed infants unless they are weaned to
at least 500 milliliter (mL)/d of vitamin D-fortified
formula or milk.
• All nonbreast-fed infants who are ingesting less
than 500 mL/d of vitamin D-fortified formula or
milk.
• Children and adolescents who do not get regular
sunlight exposure, do not ingest at least 500 mL/
d of vitamin D-fortified milk, or do not take a daily
multivitamin supplement containing at least 200 IU
of vitamin D.
PO 00000
Frm 00017
Fmt 4700
Sfmt 4700
69437
included a UL for vitamin D for infants,
children, and adults. The IOM UL for
vitamin D for children 1 to 18 years of
age and adults is 2,000 IU/p/d. The UL
for infants less than 1 year of age is
1,000 IU/p/d.
The IOM considers the UL as the
highest daily intake level of a nutrient
that is unlikely to pose a risk of adverse
effects when the nutrient is consumed
over long periods of time. The UL is
determined using a risk assessment
model developed specifically for
nutrients and considers intake from all
sources: Food, water, nutrient
supplements, and pharmacological
agents. The dose-response assessment,
which concludes with an estimate of the
UL, is built upon three toxicological
concepts commonly used in assessing
the risk of exposures to chemical
substances: No-observed-adverse-effect
level, lowest-observed-effect level, and
an uncertainty factor.
C. Safety Assessment
To support the safety of their
proposed uses for vitamin D3, Kraft
submitted scientific articles published
subsequent to the IOM report and
issuance of the February 2003 final rule
for the use of vitamin D3 in calciumfortified fruit juices and fruit juice
drinks (68 FR 9000, February 27, 2003),
including 12 clinical studies in humans
in which subjects received both vitamin
D and calcium supplementation for
periods of up to 3 years. Kraft
concluded that the recent publications
continue to support the safe use of
vitamin D supplementation in both
animals and humans. FDA concurs with
Kraft’s conclusions.
FDA considered the UL established by
IOM for infants, children, and adults
relative to the intake estimates provided
by the petitioner as the primary basis for
assessing the safety of the proposed use
of vitamin D3 in cheese and cheese
products. For all children and adults 2
years of age and older, mean and 90th
percentile intake estimates from current
and proposed food uses of vitamin D are
well below the IOM UL of 2,000 IU/p/
d. For infants 0 to 11 months of age,
mean and 90th percentile intakes are
below the UL of 1000 IU/p/d.
Additionally, when dietary supplements
are included in the calculations, intake
estimates remain below the UL. Because
the EDI of vitamin D from all sources is
less than the UL, the agency concludes
that dietary exposure of vitamin D3 from
its proposed use as a nutrient
supplement in cheese and cheese
products will not pose a safety concern.
E:\FR\FM\16NOR1.SGM
16NOR1
69438
Federal Register / Vol. 70, No. 220 / Wednesday, November 16, 2005 / Rules and Regulations
III. Conclusion
Based on all data relevant to vitamin
D3 reviewed by the agency, FDA
concludes that there is a reasonable
certainty that no harm will result from
the use of vitamin D3 as a nutrient
supplement in cheese and cheese
products, excluding cottage cheese,
ricotta cheese, and hard grating cheeses,
such as Parmesan and Romano as
defined in §§ 133.165 and 133.183,
respectively, and those defined by the
standard of identity in § 133.148, at
levels up to 81 IU/30 g of cheese. Thus,
vitamin D3 is safe for the proposed use
and the agency concludes that the food
additive regulations should be amended
as set forth in this document. To ensure
that only food grade vitamin D3 is used
in food, the additive must meet the
specifications set forth in § 172.380.
In accordance with § 171.1(h) (21 CFR
171.1(h)), the petition and the
documents that FDA considered and
relied upon in reaching its decision to
approve the petition are available for
inspection at the Center for Food Safety
and Applied Nutrition by appointment
with the information contact person (see
FOR FURTHER INFORMATION CONTACT). As
provided in § 171.1(h), the agency will
delete from the documents any
materials that are not available for
public disclosure before making the
documents available for inspection.
IV. Environmental Effects
The agency has previously considered
the environmental effects of this rule as
announced in the notice of filing for
FAP 4A4758. No new information or
comments have been received that
would affect the agency’s previous
determination that there is no
significant impact on the human
environment and that an environmental
impact statement is not required.
V. Paperwork Reduction Act of 1995
This final rule contains no collection
of information. Therefore, clearance by
the Office of Management and Budget
under the Paperwork Reduction Act of
1995 is not required.
VI. Objections
Any person who will be adversely
affected by this regulation may file with
the Division of Dockets Management
(see ADDRESSES) written or electronic
objections. Each objection shall be
separately numbered, and each
numbered objection shall specify with
particularity the provisions of the
regulation to which objection is made
and the grounds for the objection. Each
numbered objection on which a hearing
is requested shall specifically so state.
Failure to request a hearing for any
VerDate Aug<31>2005
14:56 Nov 15, 2005
Jkt 208001
particular objection shall constitute a
waiver of the right to a hearing on that
objection. Each numbered objection for
which a hearing is requested shall
include a detailed description and
analysis of the specific factual
information intended to be presented in
support of the objection in the event
that a hearing is held. Failure to include
such a description and analysis for any
particular objection shall constitute a
waiver of the right to a hearing on the
objection. For written objections, three
copies of all documents shall be
submitted and shall be identified with
the docket number found in brackets in
the heading of this document. Any
objections received in response to the
regulation may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
VII. Reference
The following reference has been
placed on display at the Division of
Dockets Management (see ADDRESSES)
and may be seen by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday.
1. Memorandum from Folmer, Division of
Petition Review, Chemistry Review Group, to
Kidwell, Division of Petition Review,
February 2, 2005.
List of Subjects in 21 CFR Part 172
Food additives, Reporting and
recordkeeping requirements.
I Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs, 21 CFR part 172 is
amended as follows:
PART 172—FOOD ADDITIVES
PERMITTED FOR DIRECT ADDITION
TO FOOD FOR HUMAN
CONSUMPTION
1. The authority citation for 21 CFR
part 172 continues to read as follows:
I
Authority: 21 U.S.C. 321, 341, 342, 348,
371, 379e.
2. Section 172.380 is amended by
adding paragraph (c)(5) to read as
follows:
I
§ 172.380
Vitamin D3.
*
*
*
*
*
(c) * * *
(5) At levels not to exceed 81 IU per
30 grams in cheese and cheese products
as defined under § 170.3(n)(5) of this
chapter, excluding cottage cheese,
ricotta cheese, and hard grating cheeses
such as Parmesan and Romano as
defined in §§ 133.165 and 133.183 of
this chapter, and those defined by
standard of identity in § 133.148 of this
chapter.
PO 00000
Frm 00018
Fmt 4700
Sfmt 4700
Dated: November 4, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–22670 Filed 11–15–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 520
Oral Dosage Form New Animal Drugs;
Tylosin
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final rule.
SUMMARY: The Food and Drug
Administration (FDA) is amending the
animal drug regulations to reflect
approval of a supplemental new animal
drug application (NADA) filed by
Elanco Animal Health. The
supplemental NADA provides for use of
tylosin soluble powder in honey bees
for the control of American foulbrood
(Paenibacillus larvae).
DATES: This rule is effective November
16, 2005.
FOR FURTHER INFORMATION CONTACT: Joan
C. Gotthardt, Center for Veterinary
Medicine (HFV–130), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 301–827–7571, email: joan.gotthardt@fda.gov.
SUPPLEMENTARY INFORMATION: Elanco
Animal Health, A Division of Eli Lilly
& Co., Lilly Corporate Center,
Indianapolis, IN 46285, filed a
supplement to NADA 13 076 that
provides for the use of TYLAN (tylosin
tartrate) Soluble in honey bees for the
control of American foulbrood
(Paenibacillus larvae). The approval of
this supplemental NADA relied on
publicly available safety and
effectiveness data contained in Public
Master File (PMF) 5783 which were
compiled under National Research
Support Project 7 (NRSP 7), a national
agricultural research program for
obtaining clearances for use of new
drugs in minor animal species and for
special uses. The supplemental NADA
is approved as of October 17, 2005, and
the regulations in 21 CFR 520.2640 are
amended to reflect the approval. The
basis of approval is discussed in the
freedom of information summary.
In accordance with the freedom of
information provisions of 21 CFR part
20 and 21 CFR 514.11(e)(2)(ii), a
summary of safety and effectiveness
data and information submitted to
support approval of this application
E:\FR\FM\16NOR1.SGM
16NOR1
Agencies
[Federal Register Volume 70, Number 220 (Wednesday, November 16, 2005)]
[Rules and Regulations]
[Pages 69435-69438]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-22670]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 172
[Docket No. 2004F-0374]
Food Additives Permitted for Direct Addition to Food for Human
Consumption; Vitamin D3
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is amending the food
additive regulations to provide for the safe use of vitamin
D3 as a nutrient supplement in cheese and cheese products at
a level above that currently allowed by the regulations. This action is
in response to a petition filed by Kraft Foods Global, Inc. (Kraft).
DATES: This rule is effective November 16, 2005. Submit written or
electronic objections and requests for a hearing by December 16, 2005.
See Section VI of this document for information on the filing of
objections.
ADDRESSES: You may submit written objections and requests for a
hearing, identified by Docket No. 2004F-0374, by any of the following
methods:
Electronic Submissions
Submit electronic objections in the following ways:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Agency Web site: https://www.fda.gov/dockets/ecomments.
Written Submissions
Submit written submissions in the following ways:
FAX: 301-827-6870.
Mail/Hand delivery/Courier [For paper, disk, or CD-ROM
submissions]:
[[Page 69436]]
Division of Dockets Management (HFA-305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
To ensure more timely processing of objections, FDA is no longer
accepting objections submitted to the agency by e-mail. FDA encourages
you to continue to submit electronic objections by using the Federal
eRulemaking Portal or the agency Web site, as described in the
Electronic Submissions portion of this paragraph.
Instructions: All submissions received must include the agency name
and docket number for this rulemaking. All objections received will be
posted without change to https://www.fda.gov/ohrms/dockets/default.htm,
including any personal information provided. For detailed instructions
on submitting objections, see the ``Objections'' heading of the
SUPPLEMENTARY INFORMATION section of this document.
Docket: For access to the docket to read background documents or
objections received, go to https://www.fda.gov/ohrms/dockets/default.htm
and insert the docket number, found in brackets in the heading of this
document, into the ``Search'' box and follow the prompts and/or go to
the Division of Dockets Management, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Judith L. Kidwell, Center for Food
Safety and Applied Nutrition (HFS-265), Food and Drug Administration,
5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1071.
SUPPLEMENTARY INFORMATION:
I. Introduction
In a notice published in the Federal Register of September 9, 2004
(69 FR 54687), FDA announced that a food additive petition (FAP 4A4758)
had been filed by Kraft Foods Global, Inc., c/o Hogan and Hartson, 555
13th St. NW., Washington, DC 20004. The petition proposed to amend the
food additive regulations in Sec. 172.380 Vitamin D3 (21
CFR 172.380) to permit the use of vitamin D3 in cheese and
cheese products at a level above that permitted in Sec. 184.1950
Vitamin D (21 CFR 184.1950). Currently, under Sec. 184.1950, milk
products, which include cheese and cheese products, may be fortified
with vitamin D at a level up to 89 International Units (IU) per (/) 100
grams (g). The petitioner requested that the maximum amount of vitamin
D permitted in certain natural and processed cheeses be increased to 81
IU vitamin D3/30 g. Cheese and cheese products identified in
the petition for increased fortification levels are those with a
reference amount customarily consumed (RACC) of 30 g as defined in
Sec. 101.12 (21 CFR 101.12), including standardized and
nonstandardized natural cheese, processed cheese, cream cheese, and
cheese spreads and dips. Hard grating cheeses with smaller reference
amounts, such as Parmesan and Romano as defined in Sec. Sec. 133.165
and 133.183 (21 CFR 133.165 and 133.183), respectively, and those
defined by the standards of identity in Sec. 133.148 (21 CFR 133.148),
are not included, nor are cheeses with larger reference amounts, such
as cottage cheese or ricotta cheese. Cheese-like products made from
nondairy starting materials (e.g., soy-based products) are not
considered to be cheese and are not included. The new limit would
permit vitamin D to be added to cheese and cheese products at a level
slightly more than 20 percent of the reference daily intake (RDI) of
vitamin D/30 g serving. Under Sec. 101.54 (21 CFR 101.54), food
containing 10 to 19 percent of the RDI of a nutrient is allowed to
carry a label claim such as ``good source'' and if the level is 20
percent or more of the RDI, the food label may claim ``excellent
source.''
Under Sec. 172.380, vitamin D3 is approved for use as a
nutrient supplement in calcium-fortified fruit juices, calcium-
fortified fruit juice drinks, meal replacement and other-type bars, and
soy-protein based meal replacement beverages represented for special
dietary use in reducing or maintaining body weight. Vitamin D \1\,
including vitamin D3, also is affirmed as generally
recognized as safe (GRAS) for use in food under Sec. 184.1950 with the
following limitations:
---------------------------------------------------------------------------
\1\Vitamin D comprises a group of fat-souble seco-sterols and
comes in many forms. The two major physiologically relevant forms
are vitamin D2 and vitamin D3. Vitamin D
without a subscript represents either D2 or
D3. As used in Sec. 184.1950, the meaning of the term
vitamin D includes crystalline vitamin D2, crystalline
vitamin D3, vitamin D2 resin, and vitamin
D3 resin. Section 172.380 includes only crystalline
vitamin D3.
------------------------------------------------------------------------
Category of Food Maximum Levels in Food (as served)
------------------------------------------------------------------------
Breakfast cereals 350 IU/100 g
------------------------------------------------------------------------
Grain products and pasta 90 IU/100 g
------------------------------------------------------------------------
Milk 42 IU/100 g
------------------------------------------------------------------------
Milk products 89 IU/100 g
------------------------------------------------------------------------
Additionally, under Sec. 184.1950(c)(2) and (c)(3) vitamin D is
affirmed as GRAS for use in infant formula and margarine, respectively.
Vitamin D3, also known as cholecalciferol, is the
chemical 9,10-seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol. Humans
synthesize vitamin D3 in skin from its precursor, 7-
dehydrocholesterol under exposure to ultraviolet B radiation in
sunlight. Other sources of naturally occurring vitamin D are foods such
as butter, buttermilk, cheese, cream, eggs, fish, goat milk, meat fats
and organ meats, and mushrooms.
Vitamin D is essential for human health. The major function of
vitamin D is to maintain blood serum concentrations of calcium and
phosphorus by enhancing the absorption of these minerals from the small
intestine. Vitamin D deficiency can lead to abnormalities in calcium
and bone metabolism such as rickets in children or osteomalacia in
adults. At high levels vitamin D may be toxic. Excessive intake of
vitamin D elevates blood plasma calcium levels by increased intestinal
absorption and/or mobilization from the bone.
To ensure that vitamin D is not added to the U.S. food supply at
levels that could raise safety concerns, FDA affirmed vitamin D as GRAS
with specific limitations, as listed in Sec. 184.1950. Under 21 CFR
184.1(b)(2), an ingredient affirmed as GRAS with specific limitations
may be used in food only within such limitations, including the
category of food, functional use, and level of use. Any addition of
vitamin D to food beyond those limitations set out in Sec. 184.1950
requires either a food additive regulation or an amendment of Sec.
184.1950.
To support the safety of the proposed uses of vitamin
D3, Kraft submitted dietary intake estimates from current
and proposed uses and from naturally-occurring sources of vitamin D and
compared these intake estimates to the tolerable upper intake level
(UL) for vitamin D established by the Institute of Medicine (IOM) of
the National Academies. Kraft also submitted a number of publications
pertaining to human clinical studies on vitamin D. Based on this
information, which is discussed in section II of this document, the
petitioner concluded that the proposed use of vitamin D3 in
cheese and cheese products is safe.
II. Evaluation of Safety
To establish with reasonable certainty that a food additive is not
harmful under its intended conditions of use, FDA considers the
projected human dietary intake of the additive, the additive's
toxicological data, and other
[[Page 69437]]
relevant information (such as published literature) available to the
agency. FDA compares an individual's estimated daily intake (EDI) of
the additive from all sources to an acceptable intake level established
by toxicological data. The EDI is determined by projections based on
the amount of the additive proposed for use in particular foods and on
data regarding the amount consumed from all sources of the additive.
The agency commonly uses the EDI for the 90\th\ percentile consumer of
a food additive as a measure of high chronic dietary intake.
A. Estimated Daily Intake for Vitamin D
The petitioner provided mean and 90\th\ percentile vitamin D intake
estimates for consumers of cheese and cheese products from the
following: (1) The proposed food uses; (2) current regulated food uses
(including naturally occurring sources of vitamin D); and (3) dietary
supplements.\2\ Intake estimates for the U.S. population 2 years of age
and older were provided, as well as estimates for 18 population
subgroups, including breast-fed and nonbreast-fed infants 0 to 11
months of age. The agency agrees with the methodology used to calculate
these estimates, with the exception of intake estimates from dietary
supplements for infants 0 to 11 months of age.
---------------------------------------------------------------------------
\2\ The intake estimate included Parmesan cheese; however,
fortification of hard grating cheeses such as Parmesan was not
requested.
---------------------------------------------------------------------------
For consumers 2 years of age and older, Kraft estimated mean and
90\th\ percentile dietary intakes from current (including naturally
occurring sources) and proposed food uses of vitamin D to be 335 IU per
person per day (IU/p/d) and 582 IU/p/d, respectively. For breast-fed
infants 0 to 11 months of age, mean and 90\th\ percentile intakes were
estimated to be 180 IU/p/d and 322 IU/p/d, respectively. For nonbreast-
fed infants 0 to 11 months of age, mean and 90\th\ percentile intakes
were estimated to be 443 IU/p/d and 696 IU/p/d, respectively. For
children 1 to 3 years of age, mean and 90\th\ percentile intake
estimates were 383 IU/p/d and 583 IU/p/d, respectively.
The petitioner also considered the intake of vitamin D from dietary
supplements. The National Health and Nutrition Examination Survey III
(NHANES III) data indicate that approximately 33 percent of the U.S.
population 2 years of age and older take dietary supplements. The
NHANES III data also show that, when vitamin D is taken as a dietary
supplement, the most frequent level is 400 IU/p/d. As a conservative
estimate of intake of vitamin D from dietary supplements and
conventional food, Kraft considered it appropriate to assume that
consumers of cheese and cheese products who take dietary supplements
likely would take dietary supplements containing 400 IU of vitamin D.
They then added this value to the mean and 90\th\ percentile intake
estimates from current and proposed food uses for consumers 2 years of
age and older. For consumers of cheese and cheese products, mean and
90\th\ percentile dietary intakes from current and proposed food uses
and dietary supplements were estimated to be 735 IU/p/d and 982 IU/p/d,
respectively, for consumers 2 years of age and older. Kraft chose not
to add a value of 400 IU from supplement use to intake estimates for
infants 0 to 11 months of age due to the low percentage of infants
reported to use supplements (7 percent) in the NHANES III study. While
we do not agree with Kraft's choice to exclude supplement use in the
vitamin D intake for infants, we believe that, in light of recent
recommendations from the American Academy of Pediatrics (AAP),\3\
estimating a supplement intake of 200 IU/p/d is more appropriate than
400 IU/p/d for infants.
---------------------------------------------------------------------------
\3\ ``Prevention of Rickets and Vitamin D Deficiency: New
Guidelines for Vitamin D Intake,'' from the American Academy of
Pediatrics in: Pediatrics Vol. III No. 4, pp. 908-910, April 2003.
The AAP recommends a daily vitamin D supplement of 200 IU for the
following groups:
All breast-fed infants unless they are weaned to at
least 500 milliliter (mL)/d of vitamin D-fortified formula or milk.
All nonbreast-fed infants who are ingesting less than
500 mL/d of vitamin D-fortified formula or milk.
Children and adolescents who do not get regular
sunlight exposure, do not ingest at least 500 mL/d of vitamin D-
fortified milk, or do not take a daily multivitamin supplement
containing at least 200 IU of vitamin D.
---------------------------------------------------------------------------
Based on AAP recommendations, the agency assumed a vitamin D intake
of 200 IU from supplement use for infants 0 to 11 months of age,
resulting in exposure estimates at the 90th percentile of 522 IU/p/d
and 896 IU/p/d for breast-fed and nonbreast-fed infants, respectively.
For all other populations (including children and adolescents) we
assumed a supplement intake of 400 IU/p/d (Ref. 1).
B. Acceptable Daily Intake for Vitamin D
In 1997, the Standing Committee on the Scientific Evaluation of
Dietary Reference Intakes of the Food and Nutrition Board at IOM
conducted an extensive review of toxicology and metabolism studies on
vitamin D published through 1996. The IOM published a detailed report
that included a UL for vitamin D for infants, children, and adults. The
IOM UL for vitamin D for children 1 to 18 years of age and adults is
2,000 IU/p/d. The UL for infants less than 1 year of age is 1,000 IU/p/
d.
The IOM considers the UL as the highest daily intake level of a
nutrient that is unlikely to pose a risk of adverse effects when the
nutrient is consumed over long periods of time. The UL is determined
using a risk assessment model developed specifically for nutrients and
considers intake from all sources: Food, water, nutrient supplements,
and pharmacological agents. The dose-response assessment, which
concludes with an estimate of the UL, is built upon three toxicological
concepts commonly used in assessing the risk of exposures to chemical
substances: No-observed-adverse-effect level, lowest-observed-effect
level, and an uncertainty factor.
C. Safety Assessment
To support the safety of their proposed uses for vitamin
D3, Kraft submitted scientific articles published subsequent
to the IOM report and issuance of the February 2003 final rule for the
use of vitamin D3 in calcium-fortified fruit juices and
fruit juice drinks (68 FR 9000, February 27, 2003), including 12
clinical studies in humans in which subjects received both vitamin D
and calcium supplementation for periods of up to 3 years. Kraft
concluded that the recent publications continue to support the safe use
of vitamin D supplementation in both animals and humans. FDA concurs
with Kraft's conclusions.
FDA considered the UL established by IOM for infants, children, and
adults relative to the intake estimates provided by the petitioner as
the primary basis for assessing the safety of the proposed use of
vitamin D3 in cheese and cheese products. For all children
and adults 2 years of age and older, mean and 90th percentile intake
estimates from current and proposed food uses of vitamin D are well
below the IOM UL of 2,000 IU/p/d. For infants 0 to 11 months of age,
mean and 90\th\ percentile intakes are below the UL of 1000 IU/p/d.
Additionally, when dietary supplements are included in the
calculations, intake estimates remain below the UL. Because the EDI of
vitamin D from all sources is less than the UL, the agency concludes
that dietary exposure of vitamin D3 from its proposed use as
a nutrient supplement in cheese and cheese products will not pose a
safety concern.
[[Page 69438]]
III. Conclusion
Based on all data relevant to vitamin D3 reviewed by the
agency, FDA concludes that there is a reasonable certainty that no harm
will result from the use of vitamin D3 as a nutrient
supplement in cheese and cheese products, excluding cottage cheese,
ricotta cheese, and hard grating cheeses, such as Parmesan and Romano
as defined in Sec. Sec. 133.165 and 133.183, respectively, and those
defined by the standard of identity in Sec. 133.148, at levels up to
81 IU/30 g of cheese. Thus, vitamin D3 is safe for the
proposed use and the agency concludes that the food additive
regulations should be amended as set forth in this document. To ensure
that only food grade vitamin D3 is used in food, the
additive must meet the specifications set forth in Sec. 172.380.
In accordance with Sec. 171.1(h) (21 CFR 171.1(h)), the petition
and the documents that FDA considered and relied upon in reaching its
decision to approve the petition are available for inspection at the
Center for Food Safety and Applied Nutrition by appointment with the
information contact person (see FOR FURTHER INFORMATION CONTACT). As
provided in Sec. 171.1(h), the agency will delete from the documents
any materials that are not available for public disclosure before
making the documents available for inspection.
IV. Environmental Effects
The agency has previously considered the environmental effects of
this rule as announced in the notice of filing for FAP 4A4758. No new
information or comments have been received that would affect the
agency's previous determination that there is no significant impact on
the human environment and that an environmental impact statement is not
required.
V. Paperwork Reduction Act of 1995
This final rule contains no collection of information. Therefore,
clearance by the Office of Management and Budget under the Paperwork
Reduction Act of 1995 is not required.
VI. Objections
Any person who will be adversely affected by this regulation may
file with the Division of Dockets Management (see ADDRESSES) written or
electronic objections. Each objection shall be separately numbered, and
each numbered objection shall specify with particularity the provisions
of the regulation to which objection is made and the grounds for the
objection. Each numbered objection on which a hearing is requested
shall specifically so state. Failure to request a hearing for any
particular objection shall constitute a waiver of the right to a
hearing on that objection. Each numbered objection for which a hearing
is requested shall include a detailed description and analysis of the
specific factual information intended to be presented in support of the
objection in the event that a hearing is held. Failure to include such
a description and analysis for any particular objection shall
constitute a waiver of the right to a hearing on the objection. For
written objections, three copies of all documents shall be submitted
and shall be identified with the docket number found in brackets in the
heading of this document. Any objections received in response to the
regulation may be seen in the Division of Dockets Management between 9
a.m. and 4 p.m., Monday through Friday.
VII. Reference
The following reference has been placed on display at the Division
of Dockets Management (see ADDRESSES) and may be seen by interested
persons between 9 a.m. and 4 p.m., Monday through Friday.
1. Memorandum from Folmer, Division of Petition Review,
Chemistry Review Group, to Kidwell, Division of Petition Review,
February 2, 2005.
List of Subjects in 21 CFR Part 172
Food additives, Reporting and recordkeeping requirements.
0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs, 21 CFR part
172 is amended as follows:
PART 172--FOOD ADDITIVES PERMITTED FOR DIRECT ADDITION TO FOOD FOR
HUMAN CONSUMPTION
0
1. The authority citation for 21 CFR part 172 continues to read as
follows:
Authority: 21 U.S.C. 321, 341, 342, 348, 371, 379e.
0
2. Section 172.380 is amended by adding paragraph (c)(5) to read as
follows:
Sec. 172.380 Vitamin D3.
* * * * *
(c) * * *
(5) At levels not to exceed 81 IU per 30 grams in cheese and cheese
products as defined under Sec. 170.3(n)(5) of this chapter, excluding
cottage cheese, ricotta cheese, and hard grating cheeses such as
Parmesan and Romano as defined in Sec. Sec. 133.165 and 133.183 of
this chapter, and those defined by standard of identity in Sec.
133.148 of this chapter.
Dated: November 4, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-22670 Filed 11-15-05; 8:45 am]
BILLING CODE 4160-01-S